Implantable System News Today

Pulmonary Hypertension Emerging as a Global Health IssuePulmonary hypertension is a rapidly growing issue, especially among elderly population and in countries with the rise in aging population. The increasing pervasiveness of Pulmonary Arterial Hypertension (PAH) and a growing number of cases globally are driving d...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the...

Message : Required fields SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. "2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of...

United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 News provided by Share this article Share this article SILVER SPRING, Md. ...

Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions] I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics. Dewey Steadman -- Head of Investor Relations Good morning. Its my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. Accompanying me on to...